European Pharmaceutical Review

JUNE 8, 2023

A new report by the Association of the British Pharmaceutical Industry (ABPI) has identified the UK biopharma industry is increasingly seeking talent with artificial intelligence (AI) and data skills to maintain competitiveness as digital technology continues to drive innovation. This has spiked from 27 in 2019 to 225 in 2022.

Biopharma 83

Biopharma Government Training Education 83

MedCity News

FEBRUARY 6, 2024

However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug’s potential competitiveness in a crowded field of contenders. Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH.

Competition 115

Competition Patients Biopharma Pharma 115

Eversana Intouch

NOVEMBER 9, 2023

Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. Yet, we know small-to-mid-sized pharma launches face a unique set of challenges. Not anymore. Download POV

Pharma 83

Pharma Biopharma Competition Marketing 83

MedCity News

JANUARY 22, 2024

If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals. In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema.

Competition 111

Competition Pharmaceutical FDA Biopharma 111

MedCity News

FEBRUARY 23, 2023

FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.

Competition 107

Competition FDA Patients Pharma 107

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

MedCity News

DECEMBER 27, 2023

Cytokinetics drug aficamten met the main goal of a pivotal test in obstructive hypertrophic cardiomyopathy. If approved, the daily pill would compete against a Bristol Myers Squibb drug projected to become a blockbuster seller.

Competition 124

Competition Biopharma Pharma 124

Pharmaceutical Technology

JULY 29, 2022

As the full consequences of the COVID-19 virus started to emerge, and many industries found themselves having to either suspend operations or move to remote working, the biopharma sector found itself on the front line facing unprecedented challenges. R&D ecosystem - Index score 6.54/10.

Biopharma 59

Biopharma Manufacturing Government Engineering 59

MedCity News

AUGUST 17, 2022

The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer. Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule.

Competition 98

Competition Leads Pharmaceutical Patients 98

pharmaphorum

NOVEMBER 24, 2022

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). The post Pharma M&A rumour mill grinds out Mirati’s name again appeared first on.

Pharma 100

Pharma Biopharma FDA Competition 100

MedCity News

FEBRUARY 26, 2024

Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH. Boehringer contends this drug has best-in-class potential in a competitive field that includes an Eli Lilly drug that recently posted positive Phase 2 results.

Competition 107

Competition Pharma Biopharma 107

MedCity News

JANUARY 28, 2024

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.

Competition 126

Competition Medicine Pharma Patients 126

Clarivate

MAY 31, 2023

A glance at the 2022 top selling drugs for the biggest pharma companies reveals how dependent many large pharmas are on a small basket of products – most acquired through partnerships or acquisitions – that are nearing loss of exclusivity. Pharma is placing bigger bets on a smaller number of therapeutics and technology platforms.

Pharma 52

Pharma Biopharma Medicine Competition 52

MedCity News

JULY 19, 2023

The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.

Competition 96

Competition Sales Marketing Biopharma 96

MedCity News

JUNE 16, 2023

The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.

Competition 114

Competition FDA Biopharma Pharma 114

Pharmaceutical Technology

DECEMBER 20, 2022

trillion in Q3, according to GlobalData’s Pharma Intelligence Center Companies Database. The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. The top 20 global biopharmaceutical companies exhibited a downward trend in aggregate market capitalisation by 9.1%

Biopharma 52

Biopharma Marketing Competition Sales 52

pharmaphorum

DECEMBER 28, 2022

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma industry.

Pharma 104

Pharma Pharmaceutical manufacturing Pharmaceutical Manufacturing 104

MedCity News

SEPTEMBER 29, 2023

Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies.

Competition 118

Competition Safety Pharma Biopharma 118

European Pharmaceutical Review

OCTOBER 26, 2022

With pharma/biopharma companies looking to select CDMO partners earlier than before, and in a competitive market, what approaches can be adopted? Included in this Guide to: The changing face of outsourcing. Here, EPR explores some recent trends and evolving strategies. Are you leveraging all the information from your QC data?

Biopharma 84

Biopharma Competition Pharma Management 84

MedCity News

MAY 10, 2023

A drug developed by Protalix BioTherapeutics and Chiesi Group is now FDA approved for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.

Competition 108

Competition FDA Biopharma Pharma 108

MedCity News

JUNE 26, 2023

Pfizer’s Litfulo is the first treatment approved for treating adolescents with severe alopecia areata. The drug’s approval also covers adults, were it will compete against Eli Lilly’s Olumiant.

Competition 103

Competition FDA Biopharma Pharma 103

Clarivate

DECEMBER 19, 2022

Either way, competition over employed providers among Medicare Advantage plans has only begun to heat up and UnitedHealth remains the plan to beat. Medicare provider competition appeared first on Clarivate. To learn more about how Clarivate helps life science companies navigate the fast-changing U.S.

Competition 52

Competition Retail Insurance Marketing 52

MedCity News

JANUARY 23, 2023

The FDA approved TheracosBio’s Brenzavvy as a treatment for type 2 diabetes. But before it won a regulatory nod for controlling blood glucose in adults, it was approved at a different dose (with flavor) as a veterinary product.

Competition 98

Competition FDA Biopharma Pharma 98

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. Historically, competitive and market analysis data has been stored in spreadsheets. Truly understanding the competitive landscape and market environment.

Competition 86

Competition Marketing Pharma Biopharma 86

Pharmaceutical Technology

JUNE 15, 2023

AI in pharma R&D is one of the latest innovations helping teams apply existing knowledge to new problems. Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. Here are a few ways AI is used in pharma today.

Pharma 52

Pharma Management Networking Manufacturing 52

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.

Biopharma 111

Biopharma Pharma Marketing Management 111

MedCity News

DECEMBER 13, 2022

Amgen’s Lumakras became the first FDA-approved drug that addresses the elusive KRAS mutation, but Mirati believes its newly approved therapy, Krazati, could be better. The small molecule’s features include the ability to penetrate into the brain, where it can address cancer that has spread to the central nervous system.

Competition 106

Competition FDA Biopharma Pharma 106

Clarivate

JANUARY 23, 2024

To learn more about how Clarivate and CMR International help pharmas future-proof their portfolios, please visit us here. The post Pharma R&D productivity dips, but efficiency gains give hope appeared first on Clarivate. Jasmin Mehta is a Senior Manager within the Life Science Professional Services team at Clarivate.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

MedCity News

JUNE 16, 2023

Numerous clinical, regulatory and financial factors are behind this digital shift in pharma. And in the first quarter of this year, the largest Series A ever in digital health ($203M) went into a company accelerating clinical trials and drug development.

Pharma 119

Pharma Food and Drug Administration Recruitment Pharmacology 119

Impetus Digital

MARCH 15, 2024

Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). There are currently more than 2,000 oncology products under development.

Recruitment 94

Recruitment Healthcare Provider Patients Healthcare 94

Pharmaceutical Technology

FEBRUARY 8, 2023

The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 trillion over the past year, according to GlobalData’s Pharma Intelligence Center Companies Database. billion for 2022, according to GlobalData’s Drugs Database Pharma Intelligence Center. trillion to $3.61 to $365.84.

Marketing 78

Marketing Biopharma Sales Pharma 78

MedCity News

APRIL 5, 2024

This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie. Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis.

Competition 113

Competition Leads Biopharma Pharma 113

MedCity News

JANUARY 11, 2024

Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.

Competition 120

Competition Sales Marketing Biopharma 120

MedCity News

DECEMBER 12, 2023

A Federal Trade Commission complaint alleges the deal amounts to a monopoly player taking out its competition. Sanofi, which markets the two primary treatments for Pompe disease, was trying to add a third one by licensing rights to a Maze Therapeutics drug candidate with a different therapeutic approach.

Competition 120

Competition Marketing Biopharma Pharma 120

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., This is supported by epidemiology data from Evaluate Pharma. Europe, and parts of Asia.

Marketing 59

Marketing Biopharma Government Pharma 59

Pharmaceutical Technology

JUNE 29, 2022

Meanwhile, the pharma industry is undergoing somewhat of a transformation itself. According to Laursen, the decision to break into speciality enzymes was based on a look into the future of the biopharma market and an important assessment of how the company believes it can make a genuine difference.

Specialization 118

Specialization Biopharma B2B Sales Manufacturing 118

MedCity News

JANUARY 9, 2023

Neurocrine Biosciences is paying $175 million up front for rights to a preclinical Voyager Therapeutics gene therapy that could put the biotech in competition with Eli Lilly among other companies. Voyager could earn up to $1.5 billion in milestone payments.

Competition 124

Competition Biopharma Pharma 124